[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2002251202A1 - Intimins for the prevention or treatment of infections: i - Google Patents

Intimins for the prevention or treatment of infections: i

Info

Publication number
AU2002251202A1
AU2002251202A1 AU2002251202A AU2002251202A AU2002251202A1 AU 2002251202 A1 AU2002251202 A1 AU 2002251202A1 AU 2002251202 A AU2002251202 A AU 2002251202A AU 2002251202 A AU2002251202 A AU 2002251202A AU 2002251202 A1 AU2002251202 A1 AU 2002251202A1
Authority
AU
Australia
Prior art keywords
intimins
infections
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002251202A
Inventor
Gordon Dougan
Gadi Frankel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0107840A external-priority patent/GB0107840D0/en
Priority claimed from GB0107837A external-priority patent/GB0107837D0/en
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Publication of AU2002251202A1 publication Critical patent/AU2002251202A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002251202A 2001-03-29 2002-03-26 Intimins for the prevention or treatment of infections: i Abandoned AU2002251202A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0107840.1 2001-03-29
GB0107837.7 2001-03-29
GB0107840A GB0107840D0 (en) 2001-03-29 2001-03-29 Biological materials and methods for use in the prevention or treatment of infections:I
GB0107837A GB0107837D0 (en) 2001-03-29 2001-03-29 Biological materials and methods for use in the prevention or treatment of infections:II
PCT/GB2002/001447 WO2002079240A2 (en) 2001-03-29 2002-03-26 Intimins for the prevention or treatment of infections: i

Publications (1)

Publication Number Publication Date
AU2002251202A1 true AU2002251202A1 (en) 2002-10-15

Family

ID=26245909

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002251202A Abandoned AU2002251202A1 (en) 2001-03-29 2002-03-26 Intimins for the prevention or treatment of infections: i
AU2002241162A Abandoned AU2002241162A1 (en) 2001-03-29 2002-03-26 Intimins in the prevention or treatment of infections:ii

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2002241162A Abandoned AU2002241162A1 (en) 2001-03-29 2002-03-26 Intimins in the prevention or treatment of infections:ii

Country Status (3)

Country Link
EP (1) EP1372709A2 (en)
AU (2) AU2002251202A1 (en)
WO (2) WO2002079240A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1305525C (en) * 2004-03-27 2007-03-21 中国人民解放军第三军医大学 0157 bacterium gene engineering multivalence subunit vaccine of human and sensitive animals and its preparing method
GB2473523A (en) * 2009-09-10 2011-03-16 Solus Scient Solutions Ltd Nalidixic acid and lithium in a base medium for the culture of Listeria
CN103212060B (en) * 2013-04-23 2014-11-05 中国人民解放军军事医学科学院微生物流行病研究所 Application of protein and composition thereof in preparation of product used for preventing, diagnosing or treating EHEC (Enterohemorrhagic Escherichia Coli) infection
CN105821065A (en) * 2016-04-29 2016-08-03 南方医科大学 Double-antigen recombinant protein and preparation method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6942861B2 (en) * 1996-04-19 2005-09-13 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
EP0895543B1 (en) * 1996-04-19 2006-06-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens
GB9803322D0 (en) * 1998-02-16 1998-04-15 Imperial College Methods
GB9901897D0 (en) * 1999-01-29 1999-03-17 Imp College Innovations Ltd Biological material and use thereof
EP2295075A1 (en) * 2001-01-04 2011-03-16 University Of Saskatchewan Enterohemorragic escherichia coli vaccine

Also Published As

Publication number Publication date
WO2002079240A3 (en) 2003-06-26
AU2002241162A1 (en) 2002-10-15
WO2002079240A2 (en) 2002-10-10
WO2002079247A3 (en) 2003-10-30
WO2002079247A2 (en) 2002-10-10
EP1372709A2 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
GB0125222D0 (en) Composition for the treatment of microbial infections
AU2002310325A1 (en) Use of ozone for the prevention of infection caused by medical devices
IL160187A0 (en) Aerosolized decongestants for the treatment of sinusitis
AU2002342613A1 (en) Treatment for wounds
EP1390029A4 (en) Phenylindoles for the treatment of hiv
AU2003901008A0 (en) Composition for the treatment and prevention of bacterial infections
AU2001272852A1 (en) Composition for the treatment of migraine
AU2002303502A1 (en) Improved leads for the treatment of patients with chf
AU2002356868A1 (en) Methods for the prevention or treatment of bacterial and fungal infections
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
AU2001269704A1 (en) Oxazinoquinolones useful for the treatment of viral infections
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
AU2003291886A1 (en) Thiophenederivatives for the treatment of flavivirus infections
AU2002236781A1 (en) Treatment for snoring
AU2002322082A1 (en) Pharmaceutical composition for the treatment of viral infection
AU2002249947A1 (en) Inhibition of protein-phosphatases for the treatment of heart failure
AU2003301012A1 (en) Use of beta-defensins for treating hiv infections
AU2002251202A1 (en) Intimins for the prevention or treatment of infections: i
AU2003263978A1 (en) 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections
AU2002302580A1 (en) Use of phyllanthus constituents for treating or preventing infections caused by hepatit
AU2002304883A1 (en) Device for the treatment of tumours
AU2001258675A1 (en) Treating infections
AU2002249891A1 (en) Compounds and methods for the diagnosis and treatment of babesia infection
AU2002354372A1 (en) Installation for the treatment of products in bulb or tuber form
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase